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Abstract 
2020, The Author(s). Olanzapine is a second-generation antipsychotic (AP) drug commonly prescribed for 
the treatment of schizophrenia. Recently, olanzapine has been found to cause brain tissue volume loss in 
rodent and primate studies; however, the underlying mechanism remains unknown. Abnormal autophagy 
and oxidative stress have been implicated to have a role in AP-induced neurodegeneration, while N-
acetylcysteine (NAC) is a potent antioxidant, shown to be beneficial in the treatment of schizophrenia. 
Here, we investigate the role of olanzapine and NAC on cell viability, oxidative stress, mitochondrial mass 
and mitophagy in hypothalamic cells. Firstly, cell viability was assessed in mHypoA-59 and mHypoA NPY/
GFP cells using an MTS assay and flow cytometric analyses. Olanzapine treated mHypoA-59 cells were 
then assessed for mitophagy markers and oxidative stress; including quantification of lysosomes, 
autophagosomes, LC3B-II, p62, superoxide anion (O2-) and mitochondrial mass. NAC (10 mM) was used 
to reverse the effects of olanzapine (100 µM) on O2−, mitochondrial mass and LC3B-II. We found that 
olanzapine significantly impacted cell viability in mHypoA-59 hypothalamic cells in a dose and time-
dependent manner. Olanzapine inhibited mitophagy, instigated oxidative stress and prompted 
mitochondrial abnormalities. NAC was able to mitigate olanzapine-induced effects. These findings 
suggest that high doses of olanzapine may cause neurotoxicity of hypothalamic neurons via increased 
production of reactive oxygen species (ROS), mitochondrial damage and mitophagy inhibition. This could 
in part explain data suggesting that APs may reduce brain volume. 
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N‑acetylcysteine prevents 
olanzapine‑induced oxidative 
stress in mHypoA‑59 hypothalamic 
neurons
Zehra Boz1, Minmin Hu2, Yinghua Yu1,2 & Xu‑Feng Huang1*
Olanzapine is a second‑generation antipsychotic (AP) drug commonly prescribed for the treatment 
of schizophrenia. Recently, olanzapine has been found to cause brain tissue volume loss in rodent 
and primate studies; however, the underlying mechanism remains unknown. Abnormal autophagy 
and oxidative stress have been implicated to have a role in AP‑induced neurodegeneration, 
while N‑acetylcysteine (NAC) is a potent antioxidant, shown to be beneficial in the treatment of 
schizophrenia. Here, we investigate the role of olanzapine and NAC on cell viability, oxidative 
stress, mitochondrial mass and mitophagy in hypothalamic cells. Firstly, cell viability was assessed 
in mHypoA‑59 and mHypoA NPY/GFP cells using an MTS assay and flow cytometric analyses. 
Olanzapine treated mHypoA‑59 cells were then assessed for mitophagy markers and oxidative 
stress; including quantification of lysosomes, autophagosomes, LC3B‑II, p62, superoxide anion  (O2–) 
and mitochondrial mass. NAC (10 mM) was used to reverse the effects of olanzapine (100 µM) on 
 O2−, mitochondrial mass and LC3B‑II. We found that olanzapine significantly impacted cell viability 
in mHypoA‑59 hypothalamic cells in a dose and time‑dependent manner. Olanzapine inhibited 
mitophagy, instigated oxidative stress and prompted mitochondrial abnormalities. NAC was able to 
mitigate olanzapine‑induced effects. These findings suggest that high doses of olanzapine may cause 
neurotoxicity of hypothalamic neurons via increased production of reactive oxygen species (ROS), 
mitochondrial damage and mitophagy inhibition. This could in part explain data suggesting that APs 
may reduce brain volume.
Olanzapine is a second-generation obesogenic antipsychotic (AP) drug prescribed for the treatment of schizo-
phrenia, bipolar mania and depression among other mental  illnesses1. It has been well documented that olanzap-
ine has the potential to cause  neurodegeneration2. For example, meta-analyses report global reduction in brain 
size, grey matter reduction, enlargement of ventricles, cortical thinning and subcortical thickening in patients 
taking AP  medication3–5. Preclinical studies demonstrate similar findings and provide a better understanding of 
isolated drug effect without the interplay of  disease6. Recently, olanzapine has been reported to cause brain tissue 
volume loss and cortical thinning in animal  studies7,8. Few reports suggest that oxidative stress, mitochondrial 
damage and autophagy inhibition have a role in AP-induced cortical  thinning9,10. However, the mechanism 
underlying AP-induced neurodegeneration remains largely ambiguous.
Reactive oxygen species (ROS) more commonly referred to as “free radicals” are mainly produced in the 
mitochondria. ROS have unpaired electrons in an oxygen atom making them highly unstable; hence, they react 
quickly with surrounding molecules in order to pair their  electrons11. This usually leads to a chain reaction which 
activates numerous signalling pathways. When ROS are transiently produced, they act as signal  molecules12. 
However, when this balance is altered, excessive ROS will cause oxidative stress that may be lethal to the  cell12. 
In this case, mitophagy—a specific type of autophagy – will attempt to maintain the cells integrity and stability 
by “recycling” damaged and long-lived mitochondria. If mitochondria are not disposed of in a timely man-
ner they release caspases which can initiate apoptosis (programmed cell death)13. Autophagy is a vital cellular 
energy generating process whereby outdated or damaged organelles such as mitochondria are degraded for 
energy re-consumption. This process improves the efficiency and longevity of the cell. Briefly, an autophagosome 
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containing membrane proteins LC3B and p62 will engulf all “recyclable” units and carry them to a lysosome. 
The autophagosome and lysosome will fuse to form an autophagolysosome. Here, the damaged cellular units 
and p62 are degraded by acidic vesicles in the lysosome and are used as an energy source. It has previously been 
noted that schizophrenia patients have a marked increase in oxidative stress markers. For example, thiobarbituric 
acid-reactive substances (TBARS) and malondiadehyde (MDA) levels in patients are significantly  increased14,15. 
Chronic olanzapine treatment also increases ROS production and MDA in SHSY5Y  cells9,16–18. Furthermore, 
autophagy has a key role in the pathophysiology of schizophrenia. For example, Beclin1 (an essential autophagy 
protein) has been found to be decreased by 40% in post-mortem hippocampal tissue of schizophrenia  patients19. 
Moreover, post-mortem analysis of brain tissue confirm increased mitophagy in schizophrenia  patients20,21. 
Interestingly, clinically approved olanzapine, haloperidol, clozapine and sertindole have been found to induce 
autophagy in neuronal  cells22–24. Therefore, it is possible that the oxidative stress and autophagy observed in 
patients is caused by AP medication.
Most literature supporting AP-induced neurodegeneration focuses on the frontal and temporal lobes, how-
ever, a 10% reduction in whole brain volume has been reported in animal models with a strong focus on grey 
matter  reductions2. The primary function of the hypothalamus is metabolic regulation, yet, the hypothalamus is 
also grey  matter25. Olanzapine is notorious for causing weight-gain and other metabolic side-effects26. It is possi-
ble this is related to the neurodegeneration of grey matter in the hypothalamus. Previous studies investigating the 
role of APs on the autophagy pathway have used SH-SY5Y cells or primary  neurons24. Therefore our study is novel 
in using hypothalamic neuronal cells to investigate the role of mitophagy in AP-induced neurodegeneration.
N-acetylcysteine (NAC) is a potent antioxidant derived from the amino acid L-cysteine and is used for the 
treatment of various conditions such as schizophrenia, amyotrophic lateral sclerosis, bipolar disorder, Alzheimer’s 
disease and various  cancers27. We hypothesise that NAC may alleviate olanzapine-induced effects on neurode-
generation via countering oxidative stress.
In this study we aimed to investigate the underlying mechanism of olanzapine-induced neurodegenera-
tion, primarily focusing on the role of oxidative stress, mitochondrial damage, and mitophagy in mHypoA-59 
hypothalamic neurons. We also tested the hypothesis that antioxidant NAC would alleviate any observed effects.
Materials and methods
Experimental design—cell culture and treatments. The mHypoA-59 hypothalamic neuronal cell line 
(Cedarlane, CLU468) and mHypoA NPY/GFP (Cedarlane, CLU499) were grown at 37 °C in a humidified 5% 
 CO2 incubator in Dulbecco’s Modified Eagle Medium (Sigma Aldrich, DMEM-5796) supplemented with or 
without 10% FBS (Bovogen Biologicals, SFBS-F) and 1% penicillin/streptomycin (ThermoFisher, 15140122). 
Trypsinized cells were seeded (1.5 × 104) in CELLSTAR Greiner 96-well flat-bottom microplates for cell viability 
and FlexStation fluorescence readings, Greiner 24-well plates (1.2 × 105) for imaging and flow cytometric analy-
sis, or (0.8 × 106) Greiner 6 well plates for immunoblotting. Cells rested for 24hrs before treatment with either 
olanzapine (Sigma-Aldrich, O1141) in the presence or absence of N-acetylcysteine (Sigma-Aldrich, A7250) as 
described in results.
MTS assay & cell viability. Cell viability was assessed using the CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay and absorbance was measured at 490 nm. Cell viability was confirmed using flow cytometric 
analysis to outline live cell population while a live-cell imager was used to illustrate these results.
Acridine orange staining. Acidic vesicles were quantified using acridine orange (AO) (Sigma-Aldrich, 
318337); a pH sensitive dye used to detect lysosomal activity. We used flow cytometry or fluorescent microscopy 
to detect FL1/orange-red vs. FL3/green fluorescence.
Cyto‑ID staining. Pre-autophagosomes, autophagosomes and autophagolysosomes were measured by 
staining with the Cyto-ID Autophagy detection kit (ENZO, 51031) followed by flow cytometric analysis.
ROS and mitochondrial stress. MitoSOX Red Mitochondrial Superoxide Indicator (ThermoFisher Sci-
entific, M36008) was used to detect mitochondrial ROS, while, MitoTracker Green FM (ThermoFisher Scien-
tific, M7514) was used to determine mitochondrial mass. Cells were stained with the given dyes followed by flow 
cytometric analyses and fluorescent imaging.
Immunoblot analysis. Cells were treated for 24hrs, harvested with lysis buffer and protein concentration 
was determined using DC Protein Assay Kit (Bio-Rad, 5000111). Samples were heated at 95  °C in Laemmli 
buffer, loaded for fractionation to 10% SDS-PAGE gels (Bio-Rad, 4561033), and then transferred into Immuno-
Blot PVDF membranes (Bio-Rad, 1620177). 5% skim milk in TBST was used as blocking buffer. Membranes 
were incubated overnight at 4◦C with the following antibodies; LC3B (Cell Signalling Technology, #2775), and 
p62 (Cell Signalling Technology, 5114) in TBST containing 1% milk. Anti-rabbit IgG conjugated with horserad-
ish peroxidase was used as the secondary antibody (Santa Cruz Biotechnology). We used ECL detection reagents 
(Sigma-Aldrich, RPN3004) and captured high resolution images with Amersham Gel Imager (GE Healthcare 
life Sciences).
Statistical analysis. Statistical analysis was performed with the SPSS program (version 21; Chicago, IL, 
United States). One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was used for multiple 
comparisons for all data as there were only two factors at any given time. This includes data for cell viability, 
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AO, MitoSOX and MitoTracker flow cytometric analysis as well as LC3B-II and p62 immunoblotting. Data were 
expressed as mean ± SEM, and p < 0.05 was considered statistically significant.
Significance statement. Olanzapine is one of the most commonly prescribed second-generation antip-
sychotic drugs. Notoriously known for metabolic side-effects such as weight gain and diabetes, olanzapine has 
also been demonstrated to cause neurodegeneration. However, there is limited mechanistic knowledge sur-
rounding this area. Here, for the first time, we demonstrate that olanzapine causes cell death in mHypoA-59 
hypothalamic neurons via increased oxidative stress and mitochondrial damage. Furthermore, the antioxidant 
N-acetylcysteine is able to reverse these effects. This study provides a base-line in understanding the mechanism 
underlying olanzapine-induced neurodegeneration and proposes a potential treatment outlet for these severe 
side-effects.
Results
Olanzapine may cause neuronal toxicity in a dose and time‑dependent manner in hypotha-
lamic neurons. Hypothalamic neurons have been used in vitro to investigate central nervous system dis-
orders such as obesity, stress and metabolic  conditions28,29. An MTS assay was used to determine cell viability 
and optimum working concentrations for both mHypoA-59 neurons and mHypoA NPY/GFP after 24  h of 
olanzapine treatment. mHypoA-59 neurons were susceptible to cell toxicity at concentrations ≥ 100 µM after 
24 h (Fig. 1A; p = 0.001 ,  F(5, 47) = 12.455). In mHypoA NPY/GFP neurons, olanzapine significantly decreased cell 
viability at 200 µM (Fig. 1A’, p = 0.04,  F(4, 38) = 2.918).
Additionally, live cell images and flow cytometric quantification confirmed neurotoxicity of mHypoA-59 
neurons treated with 100 µM of olanzapine at both 24 and 48 h. 100 µM of olanzapine decreased cell viability 
at 24hrs (Fig. 1B,C, p = 0.008.  F(2, 8) = 11.928) and this was further exaggerated at 48hrs (Fig. 1D, p = 0.001. 
 F(2, 8) = 29.858). No change was observed at 25 µM.
Olanzapine causes lysosome and autophagosome accumulation in mHypoA‑59 cells. Exces-
sive or aberrant autophagy can lead to neurodegeneration and cell  death30,31. Thus, we examined the efficiency of 
the autophagy process under olanzapine treatment. AO is a fluorescent dye commonly used to detect lysosomal 
Figure 1.  Olanzapine induced neuronal toxicity in a dose and time-dependent manner. (A) mHypoA-59 
neurons and (A’) mHypoA NPY/GFP neurons were incubated with various concentrations of olanzapine for 
24hrs and cell viability was assessed using an MTS assay (B–D) mHypoA-59 neurons were then treated with 
either 25 or 100 µM of olanzapine for 24 or 48hrs, cells were imaged using a live-cell imager and quantified by 
flow cytometry. (*p < 0.05, ** p < 0.01, ***p < 0.001 compared to the control group, and compared to 24 hr in 
Fig. 1D. Data is presented as mean ± SEM).
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activity. This dye usually fluoresces green and becomes orange-red upon interaction and protonation with the 
acidic vesicles found in lysosomes. Flow cytometric analysis of AO stained mHypoA-59 neurons demonstrated 
that olanzapine increases the amount of red-marked acidic vesicles in the lysosomes under serum-starved con-
ditions (Fig. 2A’, the representative histogram is illustrated in Fig. 2B, p < 0.001,  F(3, 11) = 138.872). The observed 
effect of olanzapine was also dose-dependent (Fig. 2A, p < 0.001.  F(2, 8) = 51.886). Live cell imaging analysis with 
the Lionheart FX confirmed an increase in AO stained acidic vesicles (Fig. 2C).
Cyto-ID stains autophagic vacuoles; which includes, pre-autophagosomes, autophagosomes and autophago-
lysosomes. Hence, we used Cyto-ID to determine the level of autophagic components found after olanzapine 
exposure in mHypoA-59 neurons. Flow cytometric analysis of Cyto-ID stained mHypoA-59 neurons demon-
strated that olanzapine increases the amount of autophagic vacuoles in serum-starved conditions (Fig. 2D, the 
representative histogram is illustrated in Fig. 2E, p < 0.001,  F(3, 11) = 148.547).
Figure 2.  Olanzapine caused lysosome and autophagosome accumulation in mHypoA-59 neurons in a dose-
dependent manner under serum-starved conditions. (A–C) mHypoA-59 neurons were incubated for 24hrs with 
and without 100 µM olanzapine under serum and serum-starved conditions. After staining with acridine orange 
(AO), quantification of acidic vesicles were determined as an increase in red (FL3) vs. green (FL1) using flow 
cytometry (A,B). Flow cytometric assessment of FL3 intensity (C). Respective images of A-B using a live-cell 
imager. (D,E) mHypoA-59 neurons were incubated for 24 h with or without 100 µM olanzapine under serum 
and serum-starved conditions. After staining with Cyto-ID, autophagosomes were quantified measuring an 
increase in green fluorescence (FL1) using flow cytometry (** p < 0.01, ***p < 0.001 compared to the serum only 
group). (F) mHypoA-59 neurons were incubated for 24hrs with and without 100 µM olanzapine under serum-
starved conditions, LC3B-II and p62 were assessed via immunoblotting (* p < 0.05, ***p < 0.001 compared to the 
serum only group, data is presented as mean ± SEM) Abbreviations: Ola: Olanzapine.
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LC3B-II and p62 are key proteins in the autophagy process and are commonly used as markers for autophagy 
inhibition or completion. The LC3B and p62 proteins are required to form the membrane of the autophagosome. 
While, LC3B is accumulated with autophagy upregulation, p62 is degraded upon completion of autophagy. Inter-
estingly, western blot analysis revealed a significant increase in both LC3B-II and p62 proteins indicating an aber-
rant autophagy process (Fig. 2F). LC3B-II showed a significant increase at both 25 µM (p < 0.001,  F(2,17) = 28.449) 
and 100 µM (p < 0.001). P62 also showed a significant increase at both 25 µM (p = 0.002,  F(2, 17) = 34.778) and 
100 µM (p < 0.001).
Olanzapine induces oxidative stress and mitochondrial dysfunction in mHypoA‑59 cells. Aber-
rant autophagy is commonly related to oxidative stress and mitochondrial damage. To investigate this pathway 
further, we used MitoSOX to measure ROS production. Flow cytometric analysis of MitoSOX stained mHy-
poA-59 cells revealed a significant increase of mitochondrial ROS  (O2−) in a dose-dependent manner (Fig. 3A, 
representative histogram is illustrated in Fig. 3C, p = 0.001 at 100 µM and p < 0.001 at 150 µM,  F(3, 11) = 26.887). 
This increase was also confirmed with live cell images (Fig. 3B).
Further examination of mitochondrial stress revealed an abnormality in mitochondrial mass. Flow cytometric 
analysis of MitoTracker stained mHypoA-59 cells showed that olanzapine significantly increased mitochon-
drial mass in a dose-dependent manner (Fig. 4A, representative histogram is illustrated in Fig. 4B, p < 0.001, 
 F(3, 11) = 213.787 for all concentrations). Live cell imaging with the incucyte ZOOM confirmed an increase in 
green fluorescent mitochondria (Fig. 4C). This increase in mitochondrial mass correlated with a decline in live 
cell population (Fig. 4A’, representative scatter plot is illustrated in Fig. 4D, p = 0.021 at 100 µM and p = 0.001 at 
150 µM,  F(3, 11) = 16.929). Given the autophagy pathway was inhibited; it is possible that increased mitochondrial 
mass indicates aberrant mitophagy and thereby causes cell death.
ROS inhibitor NAC reversed olanzapine‑induced oxidative stress. Among others, one route to 
instigate autophagy is oxidative stress. We found that free radicals  (O2−) are accumulated upon olanzapine treat-
ment of hypothalamic neurons. N-Acetyl Cysteine (NAC) is commonly used for ROS inhibition. Therefore, 
Figure 3.  Olanzapine increased MitoSOX – superoxide anion  (O2−) in mHypoA-59 neurons (A–C) 
mHypoA-59 neurons were incubated for 24hrs with either 50 µM, 100 µM or 150 µM of olanzapine and stained 
with MitoSOX for  O2−. (A) fold change of MitoSOX quantified by flow cytometry (B) live cell images (C) 
fluorescence intensity via flow cytometry. (*p < 0.05, ** p < 0.01, ***p < 0.001 compared to the control group – 
the control group was stained with MitoSOX however was not treated with olanzapine. Data is presented as 
mean ± SEM).
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NAC was used to ameliorate the oxidative and mitochondrial damage inflicted by olanzapine. Ranges between 
500 µM and 10 mM NAC have been used in previous literature pertaining to neuronal cell  culture32–37. Therefore, 
we performed an initial experiment with various doses of NAC (1 mM-10 mM) to reverse olanzapine-induced 
Figure 4.  Olanzapine increased mitochondrial mass but decreased the percentage of live cells in mHypoA-59 
neurons over 24hrs. (A–C) mHypoA-59 neurons were incubated for 24hrs with either 50 µM, 100 µM or 
150 µM of olanzapine and stained with MitoTracker for mitochondrial mass. (A) Fold change of mitochondrial 
mass and live cell population percentage quantified by flow cytometry. (B) Fluorescence intensity via flow 
cytometry. (C) mHypoA-59 neurons imaged with a live cell imager. (D) Live cell population at various 
concentrations of olanzapine (*p < 0.05, ** p < 0.01, ***p < 0.001 compared to the control group – the 
control group was stained with MitoTracker however was not treated with olanzapine. Data is presented as 
mean ± SEM).
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ROS detected using MitoSOX(Fig. 5A). 1 mM NAC had no effect while 5 mM (p < 0.05) and 10 mM (p < 0.001) 
reduced ROS in olanzapine treated cells. Therefore, 10 mM NAC was used for the remainder of the experiments. 
Accordingly, 10 mM NAC significantly decreased  O2− levels (Fig. 5B, p < 0.001,  F(3, 11) = 142.996) and mitochon-
drial mass (Fig. 5C. p < 0.001,  F(3, 11) = 84.548) compared to the olanzapine only treated group, when applied to 
neurons 30  min prior to olanzapine treatment. Correspondingly, LC3B-II levels significantly decreased with 
10 mM of NAC treatment compared to the olanzapine only treated group (Fig. 5D, p = 0.006,  F(2, 8) = 97.369).
Discussion
Here, using cellular techniques, we have demonstrated that (i) olanzapine induces oxidative stress, inhibits 
mitophagy and causes apoptosis in mHypoA-59 neuronal cells; (ii) NAC is able to reverse olanzapine-induced 
oxidative stress and cellular damage.
Olanzapine is generally prescribed at a range between 5–20 mg/day and dosage is usually increased in 5 mg 
intervals on a fortnightly basis. However, more and more frequently case reports confirm prescriptions above 
the recommended range. Between 1997 and 2006, the percentage of patients prescribed olanzapine above the 
licensed range of 20 mg/day increased from 16.2% to over 50%38. This is particularly the case for treatment resist-
ant patients and those presenting with acute or high levels of  psychopathology39. A study conducted between 
Figure 5.  ROS inhibitor NAC reversed olanzapine-induced oxidative stress and mitochondrial mass. (A) 
10 mM NAC dosage was established via pretreating cells with 1–10 mM for 30mins before adding 100 µM 
olanzapine for 24hrs. Neurons were then stained with MitoSOX and fluorescence intensity was quantified via 
flow cytometry (B,C) mHypoA-59 neurons were incubated for 24hrs with either 100 µM olanzapine, 10 mM 
NAC or both under serum-starved conditions. (B) neurons were quantified via flow cytometry and imaged 
following MitoSOX staining. (C) neurons were quantified via flow cytometry and imaged following MitoTracker 
staining. (D) LC3B-II was quantified after immunoblotting. Abbreviations: Ola: Olanzapine, NAC: N-acetyl 
cysteine (*p < 0.05, ** p < 0.01, ***p < 0.001, **** < 0.0001 compared to the control group, # p < 0.05, ### p < 0.001 
compared to the olanzapine group).
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nine psychiatric centres in Denmark, concluded that 80% of patients were administered between 50 and 80 mg/
day, the maximum dose being 160 mg/day40. Another study examined 58 post-mortem blood specimens and 
found a mean olanzapine concentration of 358 ng/ml with a range of 10 to 5200 ng/ml41. Since serum levels 
should not exceed 100 ng/ml, it is clear that patients are taking more than what have previously been  reported42. 
Given these accounts from clinical practice and post-mortem blood serum levels it is not uncommon that doses 
of olanzapine higher than recommended are prescribed to patients.
Therapeutic serum levels of olanzapine are reported to be between 0.1–0.3 µM43,44; however, these serum 
levels are based on patients receiving only 5–20 mg/day. Interestingly, post-mortem samples reveal an average 
of 1.1 µM olanzapine blood concentration, ranging up to 16 µM41. It is known that antipsychotics accumulate in 
brain tissue at 25–30 folds higher than serum  levels45,46. Clinical studies predict a micro molar concentration in 
the  brain47. Although in vitro doses are not exactly comparable to doses in vivo, the olanzapine concentration in 
this study ranging between 25 and 150 µM used for neuronal culture may mimic the micro molar concentration 
of olanzapine predicted in the CNS of patients.
This present study demonstrates that olanzapine induces cell death in mHypoA-59 hypothalamic neurons 
in a dose and time-dependent manner, but not mHypoA NPY/GFP cells. Interestingly, previous studies exten-
sively report the neuroprotective nature of olanzapine against various agents. For example, olanzapine (1 mg/
kg) prevents methamphetamine-induced apoptosis in the medial prefrontal cortex of rats injected daily for 
5 days48. Another study reports olanzapine (80–120 µM) neuroprotection of glutamine and serum deprived 
PC12 cells after 72 h49. Similarly, the neuroprotective nature of olanzapine (100–200 µM) is reported against 
hydrogen peroxide toxicity in PC12 cells after 24hrs of  treatment48–50. Olanzapine is also reported to increase 
cell survival in PC12 cell cultures, SH-SY5Y cells, and 3T3  preadipocytes49,51. Conversely, the neurotoxicity of 
olanzapine is not well documented in cell culture studies, particularly hypothalamic neurons. However, one 
study reports the neurotoxic nature of olanzapine (100 µM) in SH-SY5Y  cells9. Interestingly, haloperidol and 
clozapine (10–25 µM) treated primary rat neurons, significantly decreases cell viability of neurons in a dose and 
time-dependent  manner22.
Comparable to the results found in mHypoA NPY/GFP cells here, Kowalchuk et. al. report that neither 24 h 
olanzapine treatment at 20 µM or 100 µM effected cell viability in rHypoE-19 and rHypoE-46 hypothalamic 
 cells29. The variance in cell viability observed between hypothalamic cell lines could be due to higher olanzapine 
tolerability of mHypoA NPY/GFP cells compared to mHypoA-59 cells. Previously, differential responses have 
been observed in similar cell lines in reaction to hormones and other  compounds52. This can be attributed to the 
differing origin of the cell lines, differential receptor profiles or other physical properties such as the addition 
of a GFP as seen here.
Nonetheless, in vivo, there are substantial reports to suggest the neurotoxic nature of olanzapine as well as 
other antipsychotics. For example, Vernon et al.7 report brain volume reductions of 10%, primarily of grey matter, 
in rats infused with clinical levels of either olanzapine or haloperidol for 8 weeks compared to untreated controls. 
Another study in monkeys also reveals an 8–11% loss of brain volume after oral administration of olanzapine 
or haloperidol for a period of 17–27 months53,54. Here we show that olanzapine can cause hypothalamic toxicity 
in neurons, which form the bases of hypothalamic grey matter. Olanzapine causes severe metabolic side effects 
and it is possible that these are related to hypothalamic toxicity and neurodegeneration. However, a future study 
confirming this hypothesis in vivo is necessary for a better understanding of the effects of APs on grey matter.
Taken together, it is possible that olanzapine elicits neuroprotective properties in neuroblastoma and PC12 
cell lines against certain stressors, while exhibiting neurotoxic qualities in a dose and time-dependent manner 
in certain hypothalamic neurons and causes grey matter reductions in primates and rodents.
Vucicevic et al.9 report that olanzapine initiates autophagy in SH-SY5Y blastoma cells. This present study 
demonstrates that olanzapine causes an increase in autophagosomes, lysosomes, LC3B-II and p62 proteins. 
Routinely, p62 is degraded upon autophagy completion; increased LC3B-II and p62, as found in this study, 
imply interference in the autophagy process. Haloperidol and clozapine are also reported to cause an increase 
of autophagosomes, lysosomes, LC3B-II and p62 proteins in primary rat  neurons22. These APs are suggested to 
block the fusion between autophagosomes and lysosomes and thereby hinder the autophagy process. It is well 
known that aberrant autophagy may cause programmed cell death or apoptosis. Here, we confirm that olan-
zapine also inhibits the formation of autophagolysosomes in mHypoA-59 hypothalamic neurons and thereby 
causes cell death.
We demonstrate that olanzapine induces oxidative stress via increasing  O2−; the most renowned free radical 
primarily produced in the mitochondria. Further analysis also reveals a substantial increase in mitochondrial 
mass, implying a defect in the mitophagy process. Vucicevic et al.9 also report that olanzapine (100 µM) causes 
oxidative stress and mitochondrial damage in SH-SY5Y cells after 24hrs. Another study treating human blood 
samples with 80 µM and 160 µM olanzapine for 1 hr found an increase in total oxidative stress at 160 µM. 
Although 100 µM was not measured, no oxidative stress was detected at concentrations lower than 80 µM55. 
Dietrich-Muszalska et al.56 conducted a similar study where blood samples treated with 20 and 40 µM olanzapine 
for 1 and 24hrs exhibit no significance in TBARS—an oxidative stress marker. These reports are consistent with 
our findings being that a concentration of ≥ 100 µM olanzapine causes oxidative stress while lower concentra-
tions do not.
In the clinic olanzapine is reported to have antioxidant properties. For example, Al-Chalabi et al.15 report 
that administration of olanzapine 10–20 mg/day for 2 months significantly increases total antioxidant status and 
decreases MDA levels in the serum of schizophrenia patients. On the other hand, an animal study observing 
the effect of olanzapine (6 mM) on rat hepatocytes report cytotoxicity, increased ROS production, lipid per-
oxidation, mitochondrial and lysosomal damage after a mere 2 hr exposure  period57. As previously suggested, 
it is possible that low doses of olanzapine (< 100 µM) have positive implications while, high doses (≥ 100 µM) 
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may cause cellular damage via the ROS pathway. Also, ROS may be used as a biomarker to monitor possible 
olanzapine-induced toxic effects.
N-acetylcysteine is commonly used in the study of ROS and is now more often considered in psychiatric 
therapy. The aetiologies of psychiatric illnesses are multifactorial; this involves inflammatory pathways, oxidative 
stress, mitochondrial function and apoptotic pathways among  others27. NAC is able to intervene in all of these 
pathways which is why it has gained popularity in the clinical setting. For example, in a double-blind, placebo-
controlled, randomized trial of 140 participants, NAC was given in addition to regular medication for 6 months 
and an improvement in the Positive and Negative Symptoms Scale (PANSS) was  observed58. In another case study, 
a treatment-resistant patient directed to hospital with a PANSS of 143 was treated with NAC for 7 days and her 
PANSS score decreased to  5959. In this current study we found that NAC reverses olanzapine-induced oxidative 
stress, mitochondrial damage and LC3B-II. Vucicevic et al.9 also report that NAC reversed olanzapine-induced 
LC3B conversion in SH-SY5Y cells. Given that NAC has beneficial effects in schizophrenia patients, it is possible 
that NAC administered in conjunction with olanzapine may alleviate olanzapine-induced effects via regulating 
ROS and mitophagy and reinforcing the stability of hypothalamic neurons.
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